<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03907852</url>
  </required_header>
  <id_info>
    <org_study_id>TCR2-18-01</org_study_id>
    <nct_id>NCT03907852</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer</brief_title>
  <official_title>A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TCR2 Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TCR2 Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      TC-210 T cells are a novel cell therapy that consists of autologous genetically engineered T
      cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the
      CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell
      receptor (TCR) complex.

      This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently
      determine an overall response rate in patients with advanced mesothelin-expressing cancers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events.</measure>
    <time_frame>DLTs within 28 days post-treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - To evaluate the efficacy of autologous genetically modified TC-210 T cells in patients with MSLN-expressing unresectable, metastatic, or recurrent cancers as determined by overall response rate using RECIST v1.1</measure>
    <time_frame>Overall Response Rate at 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Mesothelioma</condition>
  <condition>Mesothelioma, Malignant</condition>
  <condition>Mesothelioma; Pleura</condition>
  <condition>Mesotheliomas Pleural</condition>
  <condition>Mesothelioma Peritoneum</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Cholangiocarcinoma Recurrent</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>TC-210 T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TC-210 T Cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lymphodepletion followed by TC-210 T Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fludarabine 30 mg/m2/d on days -7 through -4 and cyclophosphamide 600 mg/m2/d on days -6 through -4 followed by TC-210 T Cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MPM, cholangiocarcinoma, and ovarian cancer will receive TC-210 at the RP2D; NSCLC patients will receive TC-210 at the RP2D or TC-210 at the RP2D followed by anti-PD1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-210 T Cells</intervention_name>
    <description>TC-210 T Cells</description>
    <arm_group_label>Lymphodepletion followed by TC-210 T Cells</arm_group_label>
    <arm_group_label>Phase 2 Dose</arm_group_label>
    <arm_group_label>TC-210 T Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine</intervention_name>
    <description>fludarabine</description>
    <arm_group_label>Lymphodepletion followed by TC-210 T Cells</arm_group_label>
    <arm_group_label>Phase 2 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide</description>
    <arm_group_label>Lymphodepletion followed by TC-210 T Cells</arm_group_label>
    <arm_group_label>Phase 2 Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-PD1</intervention_name>
    <description>anti-PD1</description>
    <arm_group_label>Phase 2 Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is &gt; 18 years of age at the time the Informed Consent is signed.

          -  Patient has a pathologically confirmed diagnosis of either Malignant
             Pleural/Peritoneal Mesothelioma (MPM), Serous Ovarian Adenocarcinoma,
             Cholangiocarcinoma, or Non-Small Cell Lung Cancer (NSCLC).

          -  Patient's tumor has been pathologically reviewed by the central laboratory with
             confirmed positive MSLN expression on &gt; 50% of tumor cells that are 2+ and/or 3+ by
             immunohistochemistry.

          -  Prior to TC-210 T cell infusion, patients must have received at least 1 systemic
             standard of care therapy for metastatic or unresectable disease with more details
             provided in the clinical protocol

          -  Patient has an Eastern Cooperative Oncology Group performance status 0 or 1.

          -  Patient has a left ventricular ejection fraction &gt; 45% as measured by resting
             echocardiogram, with no clinically significant pericardial effusion.

          -  Patient is fit for leukapheresis and has adequate venous access for the cell
             collection.

          -  Patient must have adequate organ function as indicated by the laboratory values in the
             clinical protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical</last_name>
    <role>Study Chair</role>
    <affiliation>TCR2 Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical</last_name>
    <phone>617-949-5668</phone>
    <email>TC-210@tcr2.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>240-858-3159</phone>
      <email>Cathy.wagner@nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roisin O'Cearbhail, MD</last_name>
      <phone>646-608-3742</phone>
      <email>cart@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Elkins</last_name>
      <phone>215-615-6740</phone>
      <email>Katie.Elkins@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7478</phone>
      <email>cann.researchreferrals@scresearch.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-792-4384</phone>
      <email>dke@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 1, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2019</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

